Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02126046
Recruitment Status : Unknown
Verified April 2015 by Chunfu Li, Nanfang Hospital of Southern Medical University. Recruitment status was: Recruiting
First Posted : April 29, 2014
Last Update Posted : April 16, 2015
Nanfang Hospital of Southern Medical University
Information provided by (Responsible Party):
Chunfu Li, Nanfang Hospital of Southern Medical University
Allo-hematopoietic stem cell transplantation(HSCT) is the only way to cure β-thalassemia major at present. To expand donor pool，we developed a haplo-identical HSCT (Hi-HSCT) platform. But in prior Hi-HSCT using high dose post-transplant Cyclophosphamide in patients with leukemia, cytopenia post-transplant often developed, which was considered as a symptom of GVHD. Therefore, the investigators add unrelated umbilical cord blood (UCB) to the Hi-HSCT. It has reported that, as third-party cells, UCB will reduce GVHD.The purpose of this study is to determine whether unrelated UCB following Hi-HSCT can improve outcomes of Hi-HSCT in patients with β-thalassemia major.
Condition or disease
Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
12 Months to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
< 18 year old
Unrelated umbilical cord blood following Haplo-identical HSCT